Semaglutide Tied To Reduced Bone Fracture Risk

Semaglutide is associated with a 15% reduction in bone fractures and greater weight loss for people with type 2 diabetes, according to a study presented Sunday at the Endocrine Society’s annual meeting, ENDO 2026, in Chicago. The research suggests potential bone-protective effects when compared to other anti-obesity medications.

How does semaglutide affect bone health in diabetes patients?

Semaglutide belongs to a class of medicines called glucagon-like peptide-1 receptor agonists (GLP-1s) used to treat obesity and type 2 diabetes. While some previous studies indicated that rapid weight loss from GLP-1s could lead to thinner bones and fractures, moderate and slower weight loss may preserve bone mass.

Jairo Noreña, M.D., a former endocrinology fellow at Stanford University Medical Center, led a team to determine if semaglutide’s weight loss effects differed from other therapies regarding bone health. The researchers specifically compared semaglutide against dulaglutide and oral therapies including bupropion/naltrexone and phentermine/topiramate.

Did You Know? The study utilized the Atropos Health Eos electronic health record dataset, which represents 161 million patients seen in U.S. academic medical centers and community hospitals.

What were the specific results of the Stanford study?

The retrospective cohort analysis found that the semaglutide group experienced a greater reduction in body mass index (BMI) than the control group. In terms of bone health, the semaglutide group recorded 794 fractures, while the control group recorded 1,045 fractures.

The study included adults aged 18 and older with type 2 diabetes who had no prior history of osteoporosis medication use or fractures. The intervention group consisted of 26,324 patients taking semaglutide, while the control group included 33,555 patients.

Expert Insight: Samantha Carter notes that because bone fractures are expensive and can seriously diminish quality of life as patients age, these findings highlight the critical need for integrated bone health monitoring within weight-loss medical programs.

How was the research conducted?

Researchers analyzed data from January 2016 to December 2023. They focused on patients who had not previously used semaglutide before entering the control group to ensure a clear comparison between the different medication types.

Topeka man’s diabetes impacts his bone fractures

Noreña described this work as an early step in understanding how semaglutide-induced weight loss impacts bone health. He noted that fractures are painful and can significantly affect a patient’s daily life.

What may happen next for GLP-1 research?

The authors of the study recommend that prospective studies be conducted to confirm these findings. Future research could further clarify the relationship between the speed of weight loss and the preservation of bone mass.

Healthcare providers may use this data to encourage more frequent monitoring of bone health for patients enrolled in weight-loss programs. This could lead to more tailored treatment plans for those with type 2 diabetes.

Frequently Asked Questions

What is the difference in fracture counts between the two groups?
The semaglutide group had 794 fractures, while the control group, which used dulaglutide or other oral therapies, had 1,045 fractures.

Who were the participants in this study?
Participants were adults 18 years and older diagnosed with type 2 diabetes who had no prior history of fractures or use of osteoporosis medications.

What medications were compared against semaglutide?
The control group received dulaglutide or alternative oral weight-loss therapies, specifically phentermine/topiramate and bupropion/naltrexone.

Do you believe bone health monitoring should be a standard part of all medical weight-loss programs?